Archive · 2 Sep 2025
AstraZeneca Ends India Manufacturing, Citing Global Review
AstraZeneca, a drug company, is stopping its manufacturing in India.
They had a license to make products until December 2027, but they decided to give it up early.
This change is part of a larger plan to change how the company makes and sends its products worldwide.
AstraZeneca tried to sell its factory in Bengaluru, India, but they couldn't find anyone to buy it.
The company will now import its products from its other facilities.
AstraZeneca surrendered its manufacturing license in India.
The license was valid until December 2027.
The decision follows a strategic review of global manufacturing.
The company attempted to sell its Bengaluru plant.
AstraZeneca will now import products from its global facilities.
- Who
- AstraZeneca Pharma India
- What
- Surrendered its manufacturing license
- When
- June 2024
- Where
- Bengaluru, India
- Why
- As part of a global manufacturing review
- Company
- AstraZeneca Pharma India
- Action
- Surrendered manufacturing license
- License Validity
- Until December 2027
- Location
- Bengaluru, India
- Reason
- Global manufacturing review
- Date of Announcement
- June 2024
- Plant Sale Status
- Unsuccessful